Epigenetics: It’s personal

Stelvio Oncology is using the wide inter- and intra-tumoral diversity of glioblastoma multiforme (GBM) tumors to create a personalized medicine platform that drives GBM stem cells to adopt benign cell fates based on patient-specific epigenetic signatures.

According to co-founder and CEO Attila Hajdu, the company can convert cancer cells to healthy cells by taking advantage of epigenetic signatures that are unique to particular cell types or states...